

FINAL REPORT

RDFS102109 - EU Harmonised Surveillance of Antimicrobial Resistance (AMR) in *E. coli* from Retail Meats (Year 2 - Chicken)

29th March 2017

Animal and Plant Health Agency (APHA)
Woodham Lane
New Haw
Surrey
KT15 3NB.



Animal &
Plant Health
Agency

Table of contents

1.	LIABILITY STATEMENT	3
2.	EXECUTIVE SUMMARY	4
3.	LAY PERSON'S SUMMARY	8
4.	GLOSSARY	10
5.	MATERIALS AND METHODS	11
6.	RESULTS.....	16
7.	TABLES.....	19
8.	DISCUSSION	49
9.	CONCLUSIONS.....	52
10.	REFERENCES.....	53

1. **Liability statement**

*This report has been produced by **The Animal and Plant Health Agency** under a contract placed by the Food Standards Agency (the FSA). The views expressed herein are not necessarily those of the FSA. **The Animal and Plant Health Agency** warrants that all reasonable skill and care has been used in preparing this report. Notwithstanding this warranty, **The Animal and Plant Health Agency** shall not be under any liability for loss of profit, business, revenues or any special indirect or consequential damage of any nature whatsoever or loss of anticipated saving or for any increased costs sustained by the client or his or her servants or agents arising in any way whether directly or indirectly as a result of reliance on this report or of any error or defect in this report.*

2. Executive summary

In accordance with European Directive **2003/99/EC** on the monitoring of zoonoses and zoonotic agents, Member States (MS) are obliged to ensure that procedures are in place to monitor and report on the occurrence of antimicrobial resistance (AMR) in zoonotic organisms. The European Commission Implementing Decision **2013/652/EU**, which came into force **1 January 2014**, outlines the technical requirements for AMR testing, as well as the organisms and livestock species in which AMR must be monitored and reported. Mandatory requirements are set out for MS to monitor and report AMR data for *Salmonella* spp., *Campylobacter jejuni*, indicator commensal *Escherichia coli*, AmpC and extended-spectrum beta-lactamase (ESBL) *E. coli* and carbapenemase producing *E. coli*.

This report outlines the procedures put in place to fulfil these requirements for retail chicken meat in 2016 for AmpC, ESBL and carbapenem resistant *E. coli*, following European Union (EU) guidelines and methods. The requirements (with additional detailed guidance from the EU Reference Laboratory for Antimicrobial Resistance) state that 300 retail chicken should be tested by culture for *E. coli* on MacConkey agar containing 1 mg/L of the cephalosporin antibiotic cefotaxime. *E. coli* isolates cultured from such media are expected to show third generation cephalosporin resistance which may include ESBL or AmpC type resistance, and should be further tested by performing Minimum Inhibitory Concentrations (MICs) to determine their susceptibility to a panel of antibiotics. Samples were also tested for carbapenem resistant *E. coli* on chromID[®] carba and chromID[®] OXA-48 agars as recommended by the EU. Furthermore, samples were also plated to CHROMagar[™] ESBL for specific detection of ESBL-producing *E. coli* and to MacConkey agar containing 2 mg/L colistin, for detection of colistin resistant *E. coli*. These additional screening agars were added at the request of the FSA. Other additional work was requested by the FSA outside the remit of Decision 2013/652/EU, and included a multiplex PCR to detect *bla*_{CTX-M}, *bla*_{OXA}, *bla*_{SHV} and *bla*_{TEM} genes¹ for *E. coli* isolated from CHROMagar[™] ESBL, and sequencing of the *bla*_{CTX-M} genes in CTX-M positive isolates from this agar. Presumptive *E. coli* from MacConkey agar + 2 mg/L colistin were also tested for the presence of plasmid mediated colistin resistance genes *mcr1* and *mcr2*. Finally, viable counts of all samples were also determined on MacConkey agar + 1 mg/L cefotaxime and on CHROMagar[™] ESBL.

For this study, as in 2015, the Animal and Plant Health Agency (APHA) worked in conjunction with Hallmark Veterinary Compliance Services, who arranged sampling,

FINAL REPORT

collection and posting of samples to APHA, and have reported separately on the sample details.²

The number of samples allocated in each NUTS-3 area was proportional to the population. Samples were allocated to each retailer in proportion to market share based on Defra's 2013 Family Food data. The FSA provided a table showing the proportion of retail chicken purchases by weight for large supermarket chains in the UK from 2013 Family Food data.

All samples were collected from the 11 supermarket chains in the "Big Four" and "Other large supermarket" category. Only fresh chicken with skin on or off was collected. Processed, pre-prepared including goujons, ready-based, marinated, seasoned, herbed, stuffed, "cook in the bag", breaded, battered chicken, frozen or cooked chicken were all excluded. Samples were collected twice per quarter. To ensure an even distribution the average sample numbers per quarter were 79 (approx. 40 samples per sampling week).

A total of 313 samples were collected between January and December 2016 (three samples were excluded from analysis because of foreign provenance) from England (n=272), Scotland (n=20), Wales (n=11), and Northern Ireland (n=10). The types of chicken meat collected were whole chicken (n=158), chicken breast (n=79) and other cuts, including quarters, legs, thighs & drumsticks (n=76).

A bespoke in-house SOP based on published EU methods was written for the purpose of this study and agreed with the FSA before commencement of work, for the previous year's sampling. This SOP was used for this year also, but with modifications, for example the inclusion of agars for the isolation of carbapenem and colistin resistant *E. coli*. The method involved enrichment of 25 grams of meat in Buffered Peptone Water (BPW), before plating this enrichment broth to the selective agars. The method has the theoretical potential to detect one AmpC or ESBL *E. coli* in 25 grams of meat.

None of the samples were positive on the two carbapenem agars. Of the 313 samples tested, 141 (45.1%, 95% confidence interval 39.6% to 50.6%) grew on MacConkey agar + 1 mg/L cefotaxime. Between 1 and 82 samples were tested from the 11 different supermarket chains, and between 25% and 100% (only one sample tested) of samples from each supermarket gave rise to *E. coli* on MacConkey agar + 1 mg/L cefotaxime.

A total of 95 samples, representing 30.4% (95% confidence interval 25.5% to 35.7%) of samples tested overall, gave rise to growth of presumptive ESBL-producing *E. coli* on CHROMagar™ ESBL. For these 95 isolates from CHROMagar™ ESBL, 92.6% were positive for the *bla*_{CTX-M} gene by PCR, whilst 5 / 7 of the remaining isolates were positive for the *bla*_{SHV} gene, one was only positive for *bla*_{TEM} and one was negative for *bla*_{CTX-M}, *bla*_{OXA},

FINAL REPORT

*bla*_{SHV} and *bla*_{TEM} genes¹. Most of the *bla*_{CTX-M} positive isolates had the sequence of the *bla*_{CTX-M} gene determined by sequencing of PCR products, and additionally by whole genome sequencing for four isolates. Isolates were mainly sequence type *bla*_{CTX-M 1} (n = 72), with single isolates determined as *bla*_{CTX-M 15} or *bla*_{CTX-M 28} or *bla*_{CTX-M 32} or *bla*_{CTX-M 55}. The sequence types of the *bla*_{SHV} genes were not determined.

Whilst nine samples gave growth to presumptive *E. coli* on MacConkey agar + 2 mg/L colistin, none of the “sweeps” ~ 10 to 20 colonies tested by RT-PCR were positive for plasmid mediated colistin resistance genes *mcr-1* or *mcr-2*, and as such isolates were not kept for further tests.

Only 12 samples (3.8%, 95% confidence interval 2.2% to 6.6%) from 6/ 11 supermarkets gave rise to presumptive *E. coli* counts on MacConkey agar + 1 mg/L cefotaxime and / or CHROMagar™ ESBL. These counts ranged from 40 cfu/gram (detection limit) to 400 cfu/gram.

Determination of the susceptibility (MICs) of isolates to a panel of relevant antibiotics allowed phenotypic characterisation of third generation cephalosporin resistance. An ESBL phenotype was inferred if the isolates were resistant to cefotaxime and / or ceftazidime but susceptible to ceftazidime and the isolates showed clavulanate synergy with cefotaxime and / or ceftazidime. An AmpC phenotype was inferred if cefotaxime/ clavulanate and ceftazidime / clavulanate synergy was not shown and isolates were resistant to cefotaxime, ceftazidime and ceftazidime.

By MICs, 93/141 of the isolates from MacConkey agar + 1 mg/L cefotaxime were found to have an ESBL phenotype (including 3 isolates that had an AmpC/ESBL phenotype), representing 29.7% (95% confidence interval 24.9% to 35.0%) of samples tested overall; 48/141 were found to have an AmpC phenotype (excluding the 3 isolates that also had an ESBL phenotype), representing 15.3% (95% confidence interval 11.8 % to 19.7%) of samples tested overall. If including the AmpC/ESBL phenotype isolates, 16.3% (95% confidence interval 12.6% to 20.8%) of the samples tested had an AmpC phenotype.

Between 8.3% and 100% (only one sample tested), and between 0% and 33% of the samples tested per supermarket had an ESBL or AmpC phenotype respectively.

None of the 141 isolates from MacConkey agar + 1 mg/L cefotaxime were microbiologically resistant (using EUCAST ECOFFS) to the last resort carbapenem antibiotics ertapenem, imipenem and meropenem or to colistin. Additionally, none of the isolates were resistant to the antibiotics azithromycin, temocillin and tigecycline.

FINAL REPORT

Only three isolates were resistant to gentamicin and only about 25% of isolates were resistant to chloramphenicol, but as would be expected, all isolates were resistant to the beta-lactam antibiotic ampicillin. All of the isolates designated as ESBL phenotype were resistant to the cephalosporin antibiotics cefepime and ceftazidime, and all but one isolate was resistant to cefotaxime. All of the isolates designated as AmpC were resistant to ceftazidime. Most or several of the isolates were resistant to the antibiotics sulfamethoxazole (78.0%), tetracycline (74.5%) and trimethoprim (38.3%) and about 25% of the isolates were resistant to the quinolone antibiotics nalidixic acid and / or ciprofloxacin. Interestingly, isolates with an AmpC phenotype tended to show fewer strains resistant to the antibiotics cefepime, ciprofloxacin, nalidixic acid sulfamethoxazole, tetracycline and trimethoprim than isolates with an ESBL phenotype.

Overall results showed that (93) 29.7% and (51) 16.3% of retail chicken samples were positive for ESBL or AmpC phenotype *E. coli* respectively (including the 3 isolates with the combined AmpC/ESBL phenotype), based on results from MacConkey agar + 1 mg/L cefotaxime. Using CHROMagar™ ESBL, 95 (30.4%) of samples were positive for presumptive ESBL phenotype *E. coli*, of which 88 (28.1%) of samples were confirmed to be *bla*_{CTX-M} positive (mainly *bla*_{CTX-M 1}), and a further 5 isolates were positive for *bla*_{SHV}, giving 93 (29.7%) of isolates positive for either *bla*_{CTX-M} or *bla*_{SHV}. Results showed a decrease in the proportion of samples positive for ESBL-producing *E. coli* compared to a previous (2013-2014) UK study, which reported that 65.4% of 159 retail chicken samples were positive for ESBL-producing *E. coli*.³ This difference was statistically significant using a chi-squared test (odds ratio 0.45 p-value<0.001). Whilst the 2013/14 study used similar methodology, and utilised samples from three regions in England, and from Scotland and Wales, it should be noted that the slightly different sampling criteria and sample processing methods used in the current study could have influenced results. None of the samples were positive for carbapenem resistant *E. coli* or for *E. coli* positive for the plasmid mediated colistin resistance genes *mcr-1* and *mcr-2*, and only 12 meat samples had viable counts (without enrichment) of presumptive ESBL-producing *E. coli* above the detection limit (40 cfu/gram), and these counts were all less than or equal to 400 cfu/gram.

3. Lay person's summary

In accordance with European Directive **2003/99/EC** on the monitoring of bacteria that can pass from animals to humans and causes disease (zoonoses and zoonotic agents), Member States (MS) are obliged to ensure that procedures are in place to monitor and report on the occurrence of antimicrobial resistance (AMR) in such bacteria.

The requirements (with additional detailed guidance from the EU Reference Laboratory for Antimicrobial Resistance) state that 300 retail chicken should be tested by culture for the bacterium *E. coli*. *E. coli* bacteria are a normal part of the gut flora of mammals and as such can be useful “indicator” bacteria for AMR. Whilst some strains of *E. coli* can cause disease, most strains of *E. coli* can be present in healthy animals and humans.

The EU requirements state that samples should be tested on an agar that will select for resistance to antibiotics known as third generation cephalosporins, and such antibiotics are important for treating infections in humans. *E. coli* from this agar normally show two main types of resistance types known as Extended Spectrum β -lactamase (ESBL) or AmpC type resistance. Isolates from this agar were then tested by performing Minimum Inhibitory Concentrations (MICs) to determine the susceptibility / resistance of isolates to a panel of antibiotics.

EU requirements also state that samples should be tested on two agars that will select for resistance to a group of antibiotics known as carbapenems. Carbapenem antibiotics are also really important in human medicine, as they are termed “last resort” antibiotics, used to treat infections when all or almost all other treatment options are non-viable, due to the target bacteria being resistant to most / all other relevant antibiotics. Other agars used at the request of the FSA to test samples included an agar to specifically isolate *E. coli* with ESBL type resistance and an agar to isolate colistin resistant *E. coli*. Colistin is another “last resort” antibiotic, so it is important to monitor if resistance to this type of bacteria is occurring in food samples.

Other additional work requested by the FSA included genetic tests to determine what antibiotic resistance genes were associated with ESBL and colistin resistance in *E. coli* isolates. For colistin resistance, a mobile resistance gene referred to as *mcr-1* was discovered in 2015, so colistin resistant *E. coli* were tested for this gene. The *mcr-1* gene is considered particularly important as it encodes resistance to the “last resort” antibiotic colistin, and as it is mobile it has the potential to transfer resistance in the gut to other similar bacteria. Finally, extra work requested by the FSA included performing counts of antibiotic resistant (AmpC

FINAL REPORT

and ESBL type resistance only) *E. coli* in each sample, as this provides useful information on whether AmpC/ESBL positive meat samples have a low or high number of antibiotic resistant bacteria on them.

The number of samples allocated in each area was proportional to the population and .samples were collected from the 11 supermarket chains in the "Big Four" and "Other large supermarket" category. Only fresh chicken with skin on or off was collected. Samples were collected twice per quarter. To ensure an even distribution the average sample numbers per quarter were 79 (approx. 40 samples per sampling week).

A total of 313 samples were collected between January and December 2016 from England (n=272), Scotland (n=20), Wales (n=11), and Northern Ireland (n=10). The types of chicken meat collected were whole chicken (n=158), chicken breast (n=79) and other cuts, including quarters, legs, thighs & drumsticks (n=76).

Overall results showed that 93 (29.7%) and 51 (16.3%) of retail chicken samples were positive for ESBL or AmpC phenotype *E. coli* respectively. Genetic tests showed that most of the isolates that had ESBL type resistance had a gene known as the *bla*_{CTX-M-1} gene. This gene is known to confer resistance to third generation cephalosporin antibiotics and this gene has commonly been found in *E. coli* from chickens and chicken meat in other studies.

None of the samples were positive for *E. coli* resistant to the last resort carbapenem antibiotics or for *E. coli* positive for the plasmid mediated colistin resistance genes *mcr-1*. Only 12 meat samples had counts of presumptive ESBL-producing *E. coli* above the detection limit of 40 bacteria per gram of meat, and these counts were all less than or equal to 400 bacteria per gram of meat.

Results showed a decrease in the proportion of samples positive for ESBL-producing *E. coli* compared to a previous (2013-2014) UK study, which reported that 65.4% of 159 retail chicken samples were positive for ESBL-producing *E. coli*.³ The differences were statistically significant. However, whilst the 2013/14 study used similar methodology, and utilised samples from three regions in England, and from Scotland and Wales, it should be noted that the slightly different sampling criteria and sample processing methods used in the current study could have influenced results.

4. Glossary

AmpC phenotype – A phenotype of resistance to cephalosporin antibiotics such as cephalothin, cefazolin, cefoxitin, most penicillins, and β -lactamase inhibitor- β -lactam combinations.

AmpC enzyme – Enzyme conferring AmpC type resistance

AMR – Antimicrobial resistance

APHA – Animal and Plant Health Agency

BPW – Buffered Peptone broth, a liquid media widely used to grow bacteria

CRL – Community Reference Laboratory

CTX-M – group of ESBL enzymes that give bacteria resistance to cephalosporin antibiotics.

Enterobacteriaceae – Family of bacteria including many common gut bacteria such as *Escherichia coli* or *E. coli*

CA-ESBL - CHROMagar™ ESBL, for isolation of ESBL-producing *E. coli*

CARBA - ChromID® CARBA agar, for isolation of carbapenemase resistant *E. coli*

COL - Colistin

CTX – Cefotaxime

ECOFF – Epidemiological Cut Off value (with respect to antibiotic resistance)

EN - Norme Européenne /Europäische Norm (European Standard)

ESBL – Extended Spectrum β -lactamase. Enzymes that are capable of breaking down many penicillin type antibiotics, including cephalosporin antibiotics

EU – European Union

EUCAST - European Committee on Antimicrobial Susceptibility Testing

FSA – Food Standards Agency

HCCA - α -Cyano-4-hydroxycinnamic acid

ISO - International Organisation for Standardisation

MALDI ToF – Matrix-Assisted Laser Desorption / Ionization Time-of-Flight

MCA – MacConkey agar

MCA-COL – MacConkey agar + 2 mg/L colistin

MCA-CTX - MacConkey agar + 1 mg/L cefotaxime

MIC – Minimum Inhibitory Concentration

MS – Member States

NUTS - Nomenclature of Units for Territorial Statistics

OXA-48 - ChromID® OXA-48 agar, for isolation of carbapenemase resistant *E. coli*

PBS – Phosphate Buffered saline

QC – Quality control

SOP – Standard Operating Procedure

5. Materials and Methods

All the methodology with respect to the work performed is detailed in five internal APHA Standard operating procedures (not included in this report).

These SOPs are:-

- Isolation of background (indicator commensal) and antibiotic resistant *Enterobacteriaceae* from meats and caecal contents according to CRL, EU and / or APHA protocols (CBU 0278).
- Microbank -70°C Bacterial Storage System (CBU0155).
- Storage of *Salmonella* and *E. coli* Day Cultures (CBU0093).
- Identification of Bacteria by Oxidase (BA050) and Indole Spot Test – a Rapid Method for Bacteria (BA0130) and by MALDI ToF (BAC 0334).
- Minimum Inhibitory Concentration (MIC) – The Sensititre Method (BA0604).
- Oxidase (BA050)
- Indole Spot Test – a Rapid Method for Bacteria (BA0130)
- Real Time PCR for plasmid mediated colistin resistance genes *mcr-1* and *mcr-2* (BAC0415).

The methodology for each of these aspects is summarised briefly below.

Isolation of background (indicator commensal) and antibiotic resistant *Enterobacteriaceae* from meats and caecal contents according to EU and / or APHA protocols.

The methodology follows that outlined EU documents, and the SOP CBU 0278 is based on these EU methods as below for the work outlined in this report:-

- **EU method** - Isolation of ESBL, AMPC and carbapenemase producing *E. coli* from fresh meat - October 2015
- **EU method** - Validation of selective MacConkey agar plates supplemented with 1 mg/L cefotaxime for monitoring of ESBL and AMPC producing *E. coli* in meat and animals - November 2015
- **EU method** - Validation of selective and indicative agar plates for monitoring of carbapenemase-producing *E. coli*

FINAL REPORT

Pdf files of the most recent versions of the above EU methods can be found on-line at <http://eurl-ar.eu/233-protocols.htm>.

The EU method was slightly modified in order to perform viable bacterial counts on the meat samples, as requested by the FSA. However, this modification did not affect overall the work being carried out according to EU methods.

In brief, 25 gram of meat sample collected, transported and stored under conditions as stipulated by the EU protocols, was homogenised in 75 ml of sterile chilled PBS and a small amount (~2 ml) of this homogenate was kept for viable bacterial counts. The remainder of the chilled PBS-meat homogenate was added to 150 ml of 1.66 x sterile BPW (to make 250 ml of single strength BPW), which was incubated at $37 \pm 1^\circ\text{C}$ for 18-22 hours.

The incubated BPW / meat homogenate was used to inoculate (10 μ l) MacConkey agar containing 1 mg/L cefotaxime (MCA-CTX), chromID[®] CARBA (CARBA) and chromID[®] OXA-48 (OXA-48). Samples were also plated to CHROMagar[™] ESBL (CA-ESBL), for specific detection of ESBL-producing *E. coli* and to MacConkey agar containing 2 mg/L colistin (MCA-COL), for detection of colistin resistant *E. coli*, and these were additional non-EU stipulated screening agars added at the request of the FSA.

All plates were QC tested prior to use, according to EU or APHA methods as appropriate, as outlined in the SOP.

MCA-CTX and MCA-COL plates were incubated for 18-22 hours at $44 \pm 0.5^\circ\text{C}$ before checking for lactose fermenting colonies. Other media were incubated at $37 \pm 1^\circ\text{C}$ for 18-22 hours, before checking for presumptive *E. coli*.

Lactose fermenters from MCA-CTX were assumed to be presumptive AmpC / ESBL *E. coli*, blue colonies from CA-ESBL were assumed to be presumptive ESBL-producing *E. coli* and pink to burgundy colour colonies from CARBA and OXA-48 agars were assumed to be presumptive carbapenem resistant *E. coli*. A single presumptive *E. coli* from each of these agars was plated again to the agar of origin to ensure purity prior to storage and further tests. This method has the theoretical potential to detect one *E. coli* of interest per 25 grams of meat.

From MCA-COL plates, a sweep of ~ 10 to 20 lactose fermenters (according to SOP BAC0415) was used to prepare a crude DNA sample for detection of *mcr-1* and *mcr-2* plasmid mediated colistin resistance genes by real time PCR. A sweep was taken to increase the sensitivity of detection of the *mcr* genes.

FINAL REPORT

The proportion of positive samples were calculated, and exact binomial 95% confidence intervals for each of the proportions were calculated in Stata 12 (Stata Corporation, College Station, TX, USA).

Storage of purified presumptive AMPC / EBSL *E. coli* prior to further tests

Isolates will be stored for up to five years to comply with EU requirements. Isolates were stored in duplicate, on Dorset egg slopes, and / or “bead” culture (frozen in cryogenic material at -70°C).

In brief, for Dorset egg slopes, a small amount of purified bacterial culture was aseptically transferred using a 10 µl loop from the second agar plate to the Dorset egg slope, which was then stored at room temperature. For “beads,” a larger amount of purified bacterial culture was aseptically transferred using a 10 µl loop from the second agar plate to a commercial “beads” tube. The cryogenic liquid and bacterial growth was mixed in the tube, before removing most of the supernatant cryogenic liquid, and then storing the tube at - 70°C.

Identification of Bacteria by MALDI ToF or confirmation of lactose fermenters as *E. coli* using oxidase and indole tests

For lactose fermenters isolated from MCA-CTX at 44°C, combined use of oxidase and indole tests as described by in-house SOPs, was used to confirm such isolates as *E. coli*. Presumptive *E. coli* from other agars, such as CA-ESBL, CARBA and OXA-48, were identified by MALDI ToF as described by an in-house SOP and based on that previously described.⁴

For the oxidase test and indole tests, a single well isolated colony was taken from MCA-CTX agar, plated onto blood agar and incubated overnight at 37°C. Growth from the blood agar was then used to perform oxidase and indole tests.

For the oxidase test, in-brief, a portion of bacterial colony to be tested was taken with a sterile plastic loop and rubbed onto filter paper impregnated with oxidase reagent. A deep purple colour developing within 10 seconds was taken to be “oxidase positive”. The indole test was performed in the same way, but using filter paper impregnated with James reagent (BioMerieux). Within 10 seconds, a positive reaction was indicated by the presence of a colour change to pink/red. Lactose fermenter colonies from MCA-CTX that grew at 44°C were confirmed as *E. coli* if oxidase negative and indole positive.

Isolates from non MacConkey agars prior to MALDI ToF were also grown on blood agar. A small amount of bacterial growth was applied to the metal target plate. Growth on the target

FINAL REPORT

plates was overlaid with 1 µl of 70% formic acid to perform a partial protein extraction, and allowed to dry. Each spot was then overlaid with 1 µl of HCCA matrix, and again this was allowed to dry before the target plate was loaded into the MALDI ToF machine.

Using Biotyper software, resulting spectra from the MALDI ToF run were searched against the Bruker database of spectra, and if the resulting score was ≥ 2.000 , this was taken as reliable identification to the species level.

Determination of Minimum Inhibitory Concentrations (MICs) by broth micro dilution.

MICs were performed as described in our in house SOP (BA0604), based on EN ISO 20776-1:2006.

E. coli isolates were inoculated into Mueller Hinton broth at a suitable dilution for application to commercially prepared plates containing two fold dilution series of antimicrobial compounds in accordance with Decision 2013/652/EU. After incubation at 37°C for 18 hours, the plates were examined and growth end points established for each antimicrobial to provide MIC's. Microbiologically resistant and susceptible interpretation for the MIC's were obtained by comparison with ECOFF's published by EUCAST.

For *E.coli*, the presence of carbapenemase producing strains, Extended Spectrum Beta Lactamase producers (ESBL) or AmpC enzyme producers was determined initially by assessing isolate MIC's against the microbiological breakpoints for meropenem, cefotaxime and ceftazidime. Any isolates showing a meropenem MIC's greater than 0.125mg/l, cefotaxime MIC's greater than 0.25mg/l or ceftazidime MIC's greater than 0.5mg/l were tested against a further panel of antimicrobials containing cefotaxime, ceftazidime, cefotaxime / clavulanate, ceftazidime / clavulanate, imipenem, ertapenem, temocillin, ceftazidime, cefepime and meropenem. Consequently, isolates have results reported for all of these confirmatory antimicrobials where an MIC greater than the cut off values stated above was observed for any of the screening compounds (cefotaxime, ceftazidime or meropenem) included in the first panel of antimicrobials.

Isolates confirmed resistant to meropenem were to be considered to carry a carbapenemase. The presence of ESBL producing *E.coli* strains was determined as follows: Isolates resistant to one or both of cefotaxime and ceftazidime that also had an MIC of greater than 0.125mg/l against cefepime and also showed a reduction in MIC of ≥ 8 fold against combined cefotaxime / clavulanate or ceftazidime / clavulanate when compared with the cephalosporin alone were considered to carry an ESBL.

FINAL REPORT

Isolates resistant to cefotaxime or ceftazidime that also had an MIC of greater than 8mg/l against cefoxitin and showed no reduction to MIC's or a reduction of less than three dilution steps for cefotaxime or ceftazidime in the presence of clavulanate were considered to be carrying an AmpC enzyme.

Real time PCR for plasmid mediated *mcr-1* and *mcr-2* genes

Samples that gave rise to lactose fermenting colonies on MCA-COL were tested for the presence of plasmid mediated colistin resistance genes *mcr-1* and *mcr-2* by real time (RT) PCR, according to an in-house SOP. To make detection more sensitive, a "sweep" of ~ 10 to 20 colonies was taken to prepare the crude DNA for RT-PCR.

Statistics

A simple chi-squared tests was used to compare some of the results from this study to a previous similar published study.³

6. Results

General considerations

An excellent working partnership was built up with the company contracted by FSA to supply the meat samples (HallMark Veterinary and Compliance Services) in 2015, and continued in 2016. Communication between the two organisations and all other aspects of the partnership were excellent.

All meat samples arrived within the correct temperature range, as stipulated by the EU requirements.

Details of the meat samples tested.

The background details of the meat samples tested were provided as part of the report produced by HallMark for the FSA.² Table 1 of the FSA report has been reproduced in the main in this report (Table 1) for convenience (with agreement from HallMark and the FSA). The samples collected by region and the number that were positive for AmpC / ESBL *E. coli* on MCA-CTX are shown in Table 2.

Samples positive for AmpC / ESBL *E. coli* on MCA-CTX

Of the 313 samples tested, 141 (45.1%, 95% confidence interval 39.6% to 50.6%) grew on MCA-CTX (Tables 3 and 4). Between 1 and 82 samples were tested from the 11 different supermarket chains, and between 25% and 100% (only one sample tested) of samples from each supermarket gave rise to *E. coli* on MCA-CTX (Table 5).

By MICs, 93/141 of the isolates from MCA-CTX were found to have an ESBL phenotype (Table 4), including 3 isolates that had an AmpC/ESBL phenotype, representing 29.7% (95% confidence interval 24.9% to 35.0%) of samples tested overall, and 48/141 isolates (excluding the three isolates with an AmpC/ESBL phenotype) were found to have an AmpC phenotype, representing 15.3% (95% confidence interval 11.8 % to 19.7%) of samples tested overall, or 16.3% (95% confidence interval 12.6% to 20.8%) of samples tested if isolates with an AmpC/ESBL phenotype are included (Table 5).

MIC results for isolates from MCA-CTX

Table 6 shows the individual antibiotic sensitivities for isolates from meat samples positive on MCA-CTX, from which the ESBL and AmpC phenotypes were derived.

The summary interpretation of MIC results for *E. coli* isolates from MCA-CTX for the 141 positive samples is shown in Table 7.

None of the isolates were microbiologically resistant (using EUCAST ECOFFS) to the last resort carbapenem antibiotics ertapenem, imipenem and meropenem or to colistin. Additionally, none of the isolates were resistant the antibiotics azithromycin, temocillin and tigecycline.

Most or several of the isolates were resistant to the antibiotics sulfamethoxazole, tetracycline and trimethoprim, and about 25% of the isolates were resistant to the quinolone antibiotics nalidixic acid and ciprofloxacin.

Isolates with an AmpC phenotype tended to show fewer strains resistant to the antibiotics cefepime, ciprofloxacin, nalidixic acid sulfamethoxazole, tetracycline and trimethoprim than isolates with an ESBL phenotype (Table 7).

Counts of presumptive ESBL-producing *E. coli* from MCA-CTX and CA-ESBL

Of the 313 samples tested, only 12 (3.8%, 95% confidence interval 2.2% to 6.6%) from various supermarkets gave rise to presumptive *E. coli* counts on MacConkey agar + 1 mg/L cefotaxime and / or CHROMagar™ ESBL (Table 8) above the detection limit. These counts ranged from 40 cfu/gram (detection limit) to 400 cfu/gram.

Presumptive ESBL-producing *E. coli* from CA-ESBL and PCR results

A total of 95 samples, representing 30.4% (95% confidence interval 25.5% to 35.7%) of samples tested overall, gave rise to growth of presumptive ESBL-producing *E. coli* on CA-ESBL (Table 9). For the 95 isolates from CA-ESBL, 92.6% were positive for the *bla*_{CTX-M} gene by PCR, whilst the remaining 7 isolates were mainly positive the *bla*_{SHV} gene (n = 5). Most of the *bla*_{CTX-M} positive isolates had the sequence of the *bla*_{CTX-M} gene determined by PCR and additionally by whole genome sequencing for four isolates. Isolates were mainly sequence type CTX-M 1, with one of each isolate determined as CTX-M 15 or 28 or 32 or 55. The sequence types of the *bla*_{SHV} genes were not determined.

Results of whole genome sequencing

Four isolates were found to be CTX-M 15 by sequencing of PCR amplicons, and these isolates were whole genome sequenced to determine if they were the pandemic O25: H4, ST131 clonal strain (Table 10). None of the isolates were O25: H4, ST131 (Table 10), although for one isolate, the MLST and O group was not determined, but this isolate was H31 and not H4.

Surprisingly, by WGS, only one of the four isolates was found to be CTX-M 15 and the other three were closely related CTX-M types 1 and 55. Original cultures and DNA preparations for both the WGS and the original PCR were re-tested, and all results agreed with the results from the WGS (Table 10). In previous work, on a few occasions, isolates had two CTX-M types, and it is possible that for three of the isolates CTX-M 15 was detected on first testing, but not subsequent testing. This could relate to the predominant gene type at the time of testing, if more than one CTX-M type was present.

Plasmid mediated colistin resistance genes *mcr-1* and *mcr-2*

Nine samples gave growth to presumptive *E. coli* on MCA-COL, none of the isolates tested by RT-PCR were positive for plasmid mediated colistin resistance genes *mcr-1* or *mcr-2*.

Statistics

Results showed a decrease in the proportion of samples positive for ESBL-producing *E. coli* compared to a previous (2013-2014) UK study, which reported that 65.4% of 159 retail chicken samples were positive for ESBL-producing *E. coli*.³ This difference was statistically significant using a chi-squared test (odds ratio 0.45 p-value<0.001). Whilst the 2013/14 study used similar methodology, and utilised samples from three regions in England, and from Scotland and Wales, it should be noted that the slightly different sampling criteria and sample processing methods used in the current study could have influenced results.

7. Tables

Table 1. HallMark summary of sampling strategy

Summary of Sampling Strategy	Comments and Deviations
<p style="text-align: center;">Selection of NUTS3 regions</p> <p>Based on the "MYE2: Population Estimates by single year of age and sex for local authorities in the UK, mid-2014" 109 NUTS3 regions to be selected so that they cover all 4 countries in the UK, and comprise at least 80% of the UK population.</p>	<p style="text-align: center;">No deviation</p>
<p style="text-align: center;">Sample Numbers</p> <p>The number of samples allocated in each NUTS-3 area to be proportional to the population. To account for potential loss of samples, missing data etc. an additional 5% of samples to be planned in the sampling scheme = 316 chicken samples.</p>	<p style="text-align: center;">No deviation</p>
<p>The number of chicken samples to be collected (includes 5% contingency):</p> <p style="text-align: center;"> England - 273 Scotland - 21 Wales - 11 Northern Ireland - 10 Total: 315 </p>	<p style="text-align: center;">Achieved number of samples:</p> <p style="text-align: center;"> England – 272 Scotland – 20 Wales – 11 Northern Ireland – 10 Total: 313 </p> <p style="text-align: center;">Notes on unassayable samples:</p>

FINAL REPORT

	<p>England: 2 samples unassayable due to foreign provenance. One of these was replaced with an assayable re-sample.</p> <p>Scotland: One unassayable sample due to foreign provenance.</p> <p>Unassayable samples are not listed in the final data reporting.</p>
<p>Samples to be collected twice per quarter. To ensure an even distribution the average sample numbers per quarter are 79 (approx. 40 samples per sampling week).</p>	<p style="text-align: center;">No deviations</p>
<p style="text-align: center;">Food Categories</p> <ul style="list-style-type: none"> • Whole chicken (50% of samples) • Chicken breast – including diced/sliced (25% of samples) • Other cuts – including quarters, legs, thighs, drumsticks (25% of samples) • Total planned samples: 315 <p>Collect only fresh chicken with skin on or off. Exclude processed, pre-prepared chicken including goujons, ready-based, marinated, seasoned, herbed, stuffed, “cook in the bag”, breaded or battered chicken. Also, exclude frozen or cooked chicken.</p>	<p style="text-align: center;">158 Whole chicken – 50% 79 chicken breast – 25% 76 other cuts: 24%</p> <p style="text-align: center;">Total: 313 (99% of the planned sample number. 104% of the required 300 samples).</p> <p style="text-align: center;">No deviations</p>

FINAL REPORT

<p>Target numbers for Meat Cuts</p> <p>Whole chicken: 157 Chicken breast: 79 Other cuts: 79</p>	<p>Numbers sampled: Whole chicken: 158 (1 replacement for unavailable 'other cuts') Chicken breast: 79 Other cuts: 76 (2 unassayable, 1 unavailable)</p> <p>Note: 5 samples from Northern Ireland arrived later than 24h with the lab but still under 36h; as they were still at the correct temperature and within the correct use by dates they have been listed as assayable samples</p>
<p>Selection of Retailers</p> <p>All samples to be collected from the 11 supermarket chains in the "Big Four" and "Other large supermarket" category. They are Tesco, Asda, Sainsbury's, Morrison's, Aldi, Co-op, Marks and Spencer, Waitrose, Iceland, Lidl and Spar.</p>	<p>No deviations</p>
<p>Selection of purchase points within supermarket chains and within a NUTS3 region</p> <p>Within a NUTS3 region, according to availability of the specified retail chains, surveyors are assigned specific retail outlet addresses.</p>	<p>No deviations</p>

FINAL REPORT

<p>Retailer availability</p> <p>Experience shows that surveyors find a small percentage of scheduled retail outlets changed or closed (temporarily or permanently). HallMark may need to swap the pre-assigned retailers between NUTS-3 regions in some circumstances. To be done minimising the impact and maintaining the market share %.</p>	<p>No deviations</p>
<p>Selection of specific products within each meat category</p> <p>Surveyors can freely select a sample from the randomly assigned food category and from the assigned retailer outlet.</p> <p>For a description of the sampling methodology addressing the specific evidence requirement and the objectives outlined above can be found in the Sampling Instructions for Surveyors (attached). Samples must be collected exactly as described in this document.</p>	<p>No deviations</p>
<p>Number of Samples per Retail Chain</p> <p>Samples allocated to each retailer in proportion to market share based on Defra's 2013 Family Food data. FSA provided a table showing the Proportion of retail chicken purchases by weight for large supermarket chains in the UK from 2013 Family Food data³</p>	

FINAL REPORT

Table 2. Number of samples collected by regions and isolates tested by MICs

NUTS 3 or other political structure used in sample allocation	Total number of samples collected	Number of isolates available for AMR testing (ESBL-, AmpC-producing E.coli)	Number of isolates available for AMR testing (Carbapenemase-producing E.coli)	Number of isolates tested by MICs
Aberdeen City and Aberdeenshire	3	2	0	2
Barking & Dagenham and Havering	3	1	0	1
Barnet	2	0	0	0
Barnsley, Doncaster and Rotherham	5	4	0	4
Bath and North East Somerset, North Somerset and South Gloucestershire	4	1	0	1
Berkshire	5	0	0	0
Bexley and Greenwich	3	3	0	3
Birmingham	7	6	0	6
Bournemouth and Poole	2	1	0	1
Bradford	3	1	0	1
Brent	2	0	0	0
Bristol, City of	3	2	0	2
Bromley	2	1	0	1
Buckinghamshire CC	3	1	0	1
Calderdale and Kirklees	4	1	0	1
Cambridgeshire CC	4	3	0	3
Cardiff and Vale of Glamorgan	3	1	0	1
Central Hampshire	3	1	0	1
Central Valleys	2	1	0	1
Cheshire East	2	2	0	2
Cheshire West and Chester	2	1	0	1
Clackmannanshire and Fife	3	2	0	2

FINAL REPORT

Cornwall and Isles of Scilly	3	2	0	2
Coventry	1	1	0	1
Croydon	2	2	0	2
Devon CC	5	1	0	1
Dorset CC	3	2	0	2
Dudley	2	1	0	1
Durham CC	3	1	0	1
Ealing	2	2	0	2
East Dunbartonshire, West Dunbartonshire and Helensburgh & Lomond	2	1	0	1
East Kent	3	0	0	0
East Lancashire	2	0	0	0
East Merseyside	3	1	0	1
East of Northern Ireland	3	2	0	2
East Riding of Yorkshire	2	2	0	2
East Surrey	2	1	0	1
East Sussex CC	3	0	0	0
Edinburgh, City of	3	0	0	0
Enfield	2	1	0	1
Essex Haven Gateway	3	1	0	1
Essex Thames Gateway	2	0	0	0
Flintshire and Wrexham	2	2	0	2
Glasgow City	4	2	0	2
Gloucestershire	4	2	0	2
Greater Manchester North East	4	2	0	2
Greater Manchester North West	4	1	0	1
Greater Manchester South East	3	1	0	1
Greater Manchester South West	3	2	0	2
Gwent Valleys	2	2	0	2

FINAL REPORT

Hackney and Newham	4	2	0	2
Haringey and Islington	3	2	0	2
Harrow and Hillingdon	3	1	0	1
Hartlepool and Stockton-On-Tees	2	0	0	0
Heart of Essex	2	0	0	0
Hertfordshire	7	5	0	5
Hounslow and Richmond upon Thames	3	1	0	1
Inverclyde, East Renfrewshire and Renfrewshire	2	2	0	2
Kensington & Chelsea and Hammersmith & Fulham	2	0	0	0
Kent Thames Gateway	2	0	0	0
Lambeth	2	0	0	0
Leeds	5	3	0	3
Leicester	2	1	0	1
Leicestershire CC and Rutland	4	2	0	2
Lewisham and Southwark	4	2	0	2
Lincolnshire	4	1	0	1
Liverpool	3	0	0	0
Manchester	3	0	0	0
Merton, Kingston upon Thames and Sutton	3	3	0	3
Mid Kent	2	0	0	0
Mid Lancashire	2	0	0	0
North and North East Lincolnshire	2	0	0	0
North Hampshire	2	0	0	0
North Lanarkshire	1	0	0	0
North Northamptonshire	2	0	0	0
North Nottinghamshire	3	0	0	0
North of Northern Ireland	2	1	0	1

FINAL REPORT

North Yorkshire CC	4	3	0	3
Northumberland	2	0	0	0
Norwich and East Norfolk	2	2	0	2
Nottingham	2	1	0	1
Outer Belfast	2	0	0	0
Oxfordshire	4	1	0	1
Redbridge and Waltham Forest	3	1	0	1
Sandwell	2	2	0	2
Sheffield	3	2	0	2
Shropshire CC	2	1	0	1
Somerset	3	2	0	2
South and West Derbyshire	3	2	0	2
South Hampshire	3	1	0	1
South Lanarkshire	2	0	0	0
South Nottinghamshire	2	0	0	0
South West Wales	2	2	0	2
Staffordshire CC	5	3	0	3
Suffolk	4	2	0	2
Tyneside	5	2	0	2
Wakefield	2	1	0	1
Wandsworth	2	2	0	2
Warwickshire	3	2	0	2
West and South of Northern Ireland	3	1	0	1
West Essex	2	0	0	0
West Kent	2	2	0	2
West Northamptonshire	2	1	0	1
West Surrey	5	3	0	3
West Sussex (North East)	2	2	0	2

FINAL REPORT

West Sussex (South West)	3	0	0	0
Wiltshire	3	2	0	2
Wirral	2	0	0	0
Worcestershire	4	2	0	2

FINAL REPORT

Table 3. Samples positive for ESBL phenotype *E. coli* from MCA-CTX (Grey cells indicates isolates have an AmpC/ESBL phenotype)

Sample number	Date tested	Super-market code	Food Category	Sampling Location (NUTS3)
1364243	11/10/2016	G	Other Cuts	Barnsley, Doncaster and Rotherham
1364244	11/10/2016	B	Chicken Breast	Barnsley, Doncaster and Rotherham
1364250	11/10/2016	B	Whole Chicken	Barnsley, Doncaster and Rotherham
1364252	11/10/2016	I	Whole Chicken	Sheffield
1364254	11/10/2016	A	Whole Chicken	Sheffield
1364256	13/10/2016	E	Whole Chicken	East Riding of Yorkshire
1364266	12/10/2016	D	Whole Chicken	West Northamptonshire
1364273	12/10/2016	B	Whole Chicken	South West Wales
1364277	18/10/2016	G	Other Cuts	Lewisham and Southwark
1364278	18/10/2016	K	Chicken Breast	Lewisham and Southwark
1364280	12/10/2016	K	Whole Chicken	Ealing
1364281	12/10/2016	L	Chicken Breast	Ealing
1364283	11/10/2016	A	Other Cuts	Leicestershire CC and Rutland
1364284	07/12/2016	G	Other Cuts	Gloucestershire
1364285	07/12/2016	A	Other Cuts	Gloucestershire
1364293	12/10/2016	I	Whole Chicken	Somerset
1364303	25/08/2016	B	Other Cuts	South and West Derbyshire
1364308	24/08/2016	G	Whole Chicken	Leicester
1364310	23/08/2016	K	Whole Chicken	Flintshire and Wrexham
1364311	23/08/2016	L	Whole Chicken	Cheshire East
1364314	23/08/2016	K	Chicken Breast	Cheshire West and Chester

FINAL REPORT

Sample number	Date tested	Super-market code	Food Category	Sampling Location (NUTS3)
1364325	23/08/2016	K	Whole Chicken	Aberdeen City and Aberdeenshire
1364327	23/08/2016	B	Whole Chicken	Clackmannanshire and Fife
1364332	24/08/2016	A	Whole Chicken	Inverclyde, East Renfrewshire and Renfrewshire
1364333	24/08/2016	B	Chicken Breast	Inverclyde, East Renfrewshire and Renfrewshire
1364335	24/08/2016	B	Whole Chicken	East Dunbartonshire, West Dunbartonshire and Helensburgh & Lomond
1364336	24/08/2016	L	Whole Chicken	Glasgow City
1364342	25/08/2016	I	Chicken Breast	North of Northern Ireland
1562692	19/01/2016	K	Whole Chicken	Gwent Valleys
1562695	19/01/2016	K	Chicken Breast	Cardiff and Vale of Glamorgan
1562696	19/01/2016	K	Chicken Breast	Central Valleys
1562930	24/05/2016	B	Chicken Breast	Worcestershire
1563707	12/10/2016	K	Chicken Breast	Bristol, City of
1563719	24/05/2016	I	Chicken Breast	Sandwell
1612887	07/12/2016	K	Other Cuts	Oxfordshire
1612891	08/12/2016	E	Whole Chicken	Buckinghamshire CC
1612903	07/12/2016	C	Chicken Breast	Cornwall and Isles of Scilly
1612904	07/12/2016	C	Whole Chicken	Cornwall and Isles of Scilly
1614173	15/04/2016	K	Whole Chicken	East Surrey
1614175	15/04/2016	B	Chicken Breast	West Kent
1614177	12/04/2016	K	Chicken Breast	Glasgow City
1614185	12/04/2016	K	Whole Chicken	Hounslow and Richmond upon Thames
1614188	12/04/2016	A	Chicken Breast	Redbridge and Waltham Forest
1614191	12/04/2016	A	Whole Chicken	Bexley and Greenwich

FINAL REPORT

Sample number	Date tested	Super-market code	Food Category	Sampling Location (NUTS3)
1614193	12/04/2016	K	Whole Chicken	Bexley and Greenwich
1614194	23/02/2016	G	Chicken Breast	South Hampshire
1614198	24/02/2016	B	Whole Chicken	Bournemouth and Poole
1614199	23/02/2016	G	Other Cuts	Dorset CC
1614201	24/02/2016	E	Chicken Breast	Dorset CC
1614207	25/02/2016	G	Whole Chicken	Merton, Kingston upon Thames and Sutton
1614208	25/02/2016	G	Chicken Breast	Merton, Kingston upon Thames and Sutton
1614210	23/02/2016	F	Chicken Breast	Haringey and Islington
1614212	23/02/2016	I	Chicken Breast	Haringey and Islington
1614214	14/07/2016	I	Other Cuts	West Sussex (North East)
1614219	06/07/2016	G	Chicken Breast	Warwickshire
1614229	24/02/2016	K	Whole Chicken	Norwich and East Norfolk
1614245	20/01/2016	K	Chicken Breast	West Surrey
1614250	21/01/2016	A	Whole Chicken	Croydon
1614251	21/01/2016	L	Whole Chicken	Bromley
1614255	19/01/2016	K	Chicken Breast	Suffolk
1614257	19/01/2016	K	Whole Chicken	Cambridgeshire CC
1614261	19/01/2016	B	Other Cuts	Suffolk
1614262	19/01/2016	A	Other Cuts	Cambridgeshire CC
1614268	20/01/2016	K	Other Cuts	Hertfordshire
1614270	20/01/2016	A	Whole Chicken	Hertfordshire
1614271	20/01/2016	I	Whole Chicken	Hertfordshire
1614688	24/05/2016	B	Other Cuts	Enfield

FINAL REPORT

Sample number	Date tested	Super-market code	Food Category	Sampling Location (NUTS3)
1614704	25/05/2016	C	Chicken Breast	Birmingham
1614705	25/05/2016	G	Other Cuts	Staffordshire CC
1614707	25/05/2016	L	Other Cuts	Shropshire CC
1614710	25/05/2016	J	Chicken Breast	Birmingham
1614712	25/05/2016	K	Chicken Breast	Staffordshire CC
1614714	25/05/2016	K	Whole Chicken	Birmingham
1614718	24/05/2016	K	Whole Chicken	Sandwell
1614719	24/05/2016	B	Whole Chicken	Dudley
1614723	24/05/2016	F	Chicken Breast	Lincolnshire
1614735	12/04/2016	I	Whole Chicken	Calderdale and Kirklees
1614739	12/04/2016	K	Whole Chicken	Greater Manchester North East
1614749	14/04/2016	K	Whole Chicken	Tyneside
1614753	13/04/2016	K	Whole Chicken	East of Northern Ireland
1614756	23/02/2016	K	Whole Chicken	Leeds
1614760	23/02/2016	C	Chicken Breast	North Yorkshire CC
1614762	23/02/2016	K	Chicken Breast	Leeds
1614763	23/02/2016	I	Other Cuts	North Yorkshire CC
1614764	23/02/2016	A	Other Cuts	Leeds
1614765	23/02/2016	K	Other Cuts	North Yorkshire CC
1614766	23/02/2016	G	Chicken Breast	Bradford
1614904	07/07/2016	L	Other Cuts	West Sussex (North East)
1614908	12/07/2016	I	Other cuts	Greater Manchester North West
1614911	06/07/2016	I	Chicken Breast	Wandsworth

FINAL REPORT

Sample number	Date tested	Super-market code	Food Category	Sampling Location (NUTS3)
1614913	12/07/2016	K	Whole Chicken	Greater Manchester South East
1614914	07/07/2016	L	Chicken Breast	Greater Manchester South West
1614924	24/05/2016	I	Whole Chicken	Worcestershire

FINAL REPORT

Table 4. Samples positive for AmpC phenotype *E. coli* from MCA-CTX (Grey cells indicates isolates have an AmpC/ESBL phenotype)

Sample number	Date tested	Super-market code	Food Category	Sampling Location (NUTS3)
1364251	11/10/2016	G	Whole Chicken	Barnsley, Doncaster and Rotherham
1364255	13/10/2016	D	Whole Chicken	East Riding of Yorkshire
1364258	13/10/2016	K	Other Cuts	Wakefield
1364265	11/10/2016	G	Other Cuts	Coventry
1364274	12/10/2016	B	Other Cuts	South West Wales
1364282	11/10/2016	L	Other Cuts	Leicestershire CC and Rutland
1364288	08/12/2016	F	Whole Chicken	Wiltshire
1364290	12/10/2016	K	Whole Chicken	Bristol, City of
1364300	25/08/2016	E	Chicken Breast	South and West Derbyshire
1364305	24/08/2016	K	Chicken Breast	Nottingham
1364308	24/08/2016	G	Whole Chicken	Leicester
1364309	23/08/2016	A	Chicken Breast	Flintshire and Wrexham
1364310	23/08/2016	K	Whole Chicken	Flintshire and Wrexham
1364313	23/08/2016	E	Other Cuts	Cheshire East
1364323	23/08/2016	B	Chicken Breast	Aberdeen City and Aberdeenshire
1364328	23/08/2016	K	Other Cuts	Clackmannanshire and Fife
1364345	25/08/2016	D	Whole Chicken	West and South of Northern Ireland
1562691	19/01/2016	K	Other Cuts	Gwent Valleys
1562692	19/01/2016	K	Whole Chicken	Gwent Valleys
1563611	12/10/2016	L	Chicken Breast	Bath and North East Somerset, North Somerset and South Gloucestershire
1563680	24/05/2016	A	Whole Chicken	Barking & Dagenham and Havering
1563700	12/10/2016	C	Chicken Breast	Somerset

FINAL REPORT

Sample number	Date tested	Super-market code	Food Category	Sampling Location (NUTS3)
1612881	08/12/2016	K	Chicken Breast	Durham CC
1612913	07/12/2016	C	Other Cuts	Wiltshire
1614174	15/04/2016	B	Whole Chicken	West Kent
1614189	13/04/2016	I	Whole Chicken	East of Northern Ireland
1614192	12/04/2016	K	Other Cuts	Bexley and Greenwich
1614203	23/02/2016	K	Other Cuts	Central Hampshire
1614206	25/02/2016	B	Chicken Breast	Merton, Kingston upon Thames and Sutton
1614222	06/07/2016	B	Chicken Breast	Warwickshire
1614226	06/07/2016	D	Chicken Breast	Devon CC
1614231	24/02/2016	K	Chicken Breast	Essex Haven Gateway
1614238	24/02/2016	G	Whole Chicken	Norwich and East Norfolk
1614243	20/01/2016	G	Chicken Breast	West Surrey
1614244	20/01/2016	F	Whole Chicken	West Surrey
1614249	21/01/2016	D	Whole Chicken	Croydon
1614254	19/01/2016	G	Whole Chicken	Cambridgeshire CC
1614267	20/01/2016	B	Chicken Breast	Hertfordshire
1614269	20/01/2016	K	Whole Chicken	Hertfordshire
1614681	24/05/2016	G	Whole Chicken	East Merseyside
1614708	25/05/2016	I	Other Cuts	Birmingham
1614709	25/05/2016	B	Other Cuts	Birmingham
1614713	25/05/2016	K	Other Cuts	Birmingham
1614716	25/05/2016	B	Whole Chicken	Staffordshire CC
1614738	12/04/2016	K	Other Cuts	Greater Manchester North East

FINAL REPORT

Sample number	Date tested	Super-market code	Food Category	Sampling Location (NUTS3)
1614745	14/04/2016	K	Chicken Breast	Tyneside
1614917	06/07/2016	B	Other Cuts	Wandsworth
1614919	07/07/2016	I	Other Cuts	Greater Manchester South West
1614920	05/07/2016	G	Whole Chicken	Harrow and Hillingdon
1614926	19/01/2016	G	Whole Chicken	Hackney and Newham
1614927	19/01/2016	I	Chicken Breast	Hackney and Newham

FINAL REPORT

Table 5. Number of samples per supermarket tested and that gave rise to *E. coli* on MCA-CTX with resistance phenotypes

Supermarket Code	Total number of samples tested	No. positive on McC-CTX agar (%) [*]	ESBL phenotype confirmed by MICs (%) [*]	AmpC phenotype confirmed by MICs (%) [*]	AmpC/ESBL phenotype confirmed by MICs (%) [*]
A	24	12 (50.0)	10 (41.7)	2 (8.3)	0
B	51	22 (43.1)	13 (25.5)	9 (17.7)	0
C	18	6 (33.3)	4 (22.2)	2 (11.1)	0
D	12	5 (41.7)	1 (8.3)	4 (33.3)	0
E	12	5 (41.7)	3 (25.0)	2 (16.7)	0
F	16	4 (25.0)	2 (12.5)	2 (12.5)	0
G	34	19 (55.8)	11 (32.4) **	9 (26.5) **	1 (2.9)
I	49	16 (32.7)	11 (22.4)	4 (8.2)	0
J	1	1 (100)	1 (100)	0 (0)	0
K	82	42 (51.2)	29 (35.4) **	15 (18.3) **	2 (2.4)
L	14	9 (64.3)	7 (50.0)	2 (14.3)	0

* - %'s are based on total numbers of samples tested per supermarket

** - These values include isolates with an AmpC/ESBL phenotype

FINAL REPORT

Table 6. MIC results of 20 antibiotics against all isolates from MCA-CTX

Sample no	AMP	AZM	FEP	CTX	FOX	CAZ	CHL	CIP	NAL	CST	FTP	IPM	MEM	GEN	TMC	TET	TGC	SUL	TMP
1364243	R	S	R	R	S	R	S	R	S	S	S	S	S	S	S	R	S	R	R
1364244	R	S	R	R	S	R	S	S	S	S	S	S	S	S	S	R	S	R	S
1364250	R	S	R	R	S	R	S	S	S	S	S	S	S	S	S	R	S	R	S
1364251	R	S	R	R	R	R	S	S	S	S	S	S	S	R	S	R	S	R	S
1364252	R	S	R	R	S	R	S	S	S	S	S	S	S	S	S	R	S	R	S
1364254	R	S	R	R	S	R	S	S	S	S	S	S	S	S	S	R	S	R	R
1364255	R	S	S	R	R	R	S	S	S	S	S	S	S	R	S	R	S	R	S
1364256	R	S	R	R	S	R	S	R	R	S	S	S	S	S	S	R	S	R	S
1364258	R	S	S	R	R	R	S	S	S	S	S	S	S	R	S	R	S	R	S
1364265	R	S	R	R	R	R	S	S	S	S	S	S	S	S	S	S	S	S	S
1364266	R	S	R	R	S	R	S	R	R	S	S	S	S	S	S	R	S	R	S
1364273	R	S	R	R	S	R	S	R	R	S	S	S	S	S	S	R	S	R	S
1364274	R	S	S	R	R	R	S	S	S	S	S	S	S	S	S	S	S	S	S
1364277	R	S	R	R	S	R	S	R	R	S	S	S	S	S	S	R	S	R	R
1364278	R	S	R	R	S	R	S	S	S	S	S	S	S	S	S	R	S	R	R
1364280	R	S	R	R	S	R	S	R	R	S	S	S	S	S	S	R	S	R	S
1364281	R	S	R	R	S	R	S	S	S	S	S	S	S	S	S	R	S	R	R
1364282	R	S	S	R	R	R	S	S	S	S	S	S	S	S	S	S	S	S	S
1364283	R	S	R	R	S	R	S	S	S	S	S	S	S	S	S	R	S	R	S
1364284	R	S	R	R	S	R	S	R	R	S	S	S	S	S	S	R	S	R	S
1364285	R	S	R	R	S	R	S	R	R	S	S	S	S	S	S	R	S	R	S
1364288	R	S	S	R	R	R	S	S	S	S	S	S	S	S	S	R	S	R	R
1364290	R	S	S	R	R	R	S	S	S	S	S	S	S	S	S	S	S	S	S

FINAL REPORT

1364293	R	S	R	R	S	R	S	R	R	S	S	S	S	S	R	S	R	S	
1364300	R	S	S	R	R	R	S	R	R	S	S	S	S	R	S	R	S	R	R
1364303	R	S	R	R	S	R	S	S	S	S	S	S	S	S	S	S	R	R	
1364305	R	S	R	R	R	R	S	S	S	S	S	S	S	S	R	S	S	S	
1364308	R	S	R	R	R	R	S	S	S	S	S	S	S	S	R	S	R	R	
1364309	R	S	S	R	R	R	S	S	S	S	S	S	S	S	S	S	R	R	
1364310	R	S	R	R	R	R	S	R	R	S	S	S	S	S	R	S	R	S	
1364311	R	S	R	R	S	R	S	S	S	S	S	S	S	S	R	S	R	S	
1364313	R	S	S	R	R	R	S	S	S	S	S	S	S	S	R	S	R	S	
1364314	R	S	R	R	S	R	S	R	R	S	S	S	S	S	R	S	R	S	
1364323	R	S	S	R	R	R	S	S	S	S	S	S	S	S	S	S	S	S	
1364325	R	S	R	R	S	R	S	S	S	S	S	S	S	S	R	S	R	S	
1364327	R	S	R	R	S	R	S	S	S	S	S	S	S	S	R	S	R	S	
1364328	R	S	S	R	R	R	S	S	S	S	S	S	S	S	S	S	S	S	
1364332	R	S	R	R	S	R	S	S	S	S	S	S	S	S	R	S	R	S	
1364333	R	S	R	R	S	R	S	S	S	S	S	S	S	S	S	S	S	S	
1364335	R	S	R	R	S	R	S	S	S	S	S	S	S	S	R	S	R	S	
1364336	R	S	R	R	S	R	S	R	R	S	S	S	S	S	R	S	R	S	
1364342	R	S	R	R	S	R	S	S	S	S	S	S	S	S	R	S	R	S	
1364345	R	S	S	R	R	R	S	S	S	S	S	S	S	R	S	R	S	S	
1562691	R	S	R	R	R	R	S	S	S	S	S	S	S	R	S	R	S	S	
1562692	R	S	R	R	R	R	S	R	S	S	S	S	S	R	S	R	S	S	
1562695	R	S	R	R	S	R	S	S	S	S	S	S	S	R	S	R	S	R	
1562696	R	S	R	R	S	R	S	S	S	S	S	S	S	S	R	S	R	R	
1562930	R	S	R	R	S	R	S	S	S	S	S	S	S	R	S	R	S	R	
1563611	R	S	S	R	R	R	S	R	R	S	S	S	S	S	S	S	S	S	
1563680	R	S	R	R	R	R	S	S	S	S	S	S	S	R	S	R	S	R	
1563700	R	S	S	R	R	R	S	R	R	S	S	S	S	S	S	S	S	S	

FINAL REPORT

1563707	R	S	R	R	S	R	S	S	S	S	S	S	S	S	R	S	R	S
1563719	R	S	R	R	S	R	S	R	R	S	S	S	S	R	S	S	S	S
1612881	R	S	S	R	R	R	S	S	S	S	S	S	S	S	S	S	S	S
1612887	R	S	R	R	S	R	S	S	S	S	S	S	S	S	R	S	R	S
1612891	R	S	R	R	S	R	S	S	S	S	S	S	S	S	R	S	R	R
1612903	R	S	R	R	S	R	S	S	S	S	S	S	S	S	R	S	R	S
1612904	R	S	R	R	S	R	S	S	S	S	S	S	S	S	R	S	R	S
1612913	R	S	S	R	R	R	S	R	R	S	S	S	S	S	S	S	S	S
1614173	R	S	R	R	S	R	R	R	R	S	S	S	S	S	R	S	R	R
1614174	R	S	R	R	R	R	S	S	S	S	S	S	R	S	R	S	R	S
1614175	R	S	R	R	S	R	R	R	R	S	S	S	S	S	R	S	R	R
1614177	R	S	R	R	S	R	S	S	S	S	S	S	S	S	R	S	R	S
1614185	R	S	R	R	S	R	S	S	S	S	S	S	S	S	R	S	R	R
1614188	R	S	R	R	S	R	S	S	S	S	S	S	S	S	R	S	R	R
1614189	R	S	S	R	R	R	S	R	R	S	S	S	S	S	S	S	S	S
1614191	R	S	R	R	S	R	S	S	S	S	S	S	S	S	R	S	R	R
1614192	R	S	S	R	R	R	S	S	S	S	S	S	S	S	S	S	S	S
1614193	R	S	R	R	S	R	S	S	S	S	S	S	S	S	S	S	R	R
1614194	R	S	R	R	S	R	S	S	S	S	S	S	S	S	R	S	R	R
1614198	R	S	R	R	S	R	S	S	S	S	S	S	S	S	R	S	R	S
1614199	R	S	R	R	S	R	S	S	S	S	S	S	S	S	R	S	R	S
1614201	R	S	R	R	S	R	S	S	S	S	S	S	S	S	S	S	R	R
1614203	R	S	S	R	R	R	S	S	S	S	S	S	S	S	S	S	S	S
1614206	R	S	R	R	R	R	S	S	S	S	S	S	R	S	R	S	R	S
1614207	R	S	R	R	S	R	S	S	S	S	S	S	R	S	R	S	R	R
1614208	R	S	R	R	S	R	S	S	S	S	S	S	S	S	R	S	R	R
1614210	R	S	R	R	S	R	S	S	S	S	S	S	S	S	R	S	R	S
1614212	R	S	R	R	S	R	R	R	R	S	S	S	S	S	R	S	R	R

FINAL REPORT

1614214	R	S	R	R	S	R	S	R	R	S	S	S	S	S	S	R	S	R	R
1614219	R	S	R	R	S	R	S	S	S	S	S	S	S	S	S	R	S	R	R
1614222	R	S	R	R	R	R	S	S	S	S	S	S	S	S	S	S	S	S	S
1614226	R	S	R	R	R	R	S	S	S	S	S	S	S	S	S	S	S	S	S
1614229	R	S	R	R	S	R	S	S	S	S	S	S	S	S	S	R	S	R	R
1614231	R	S	R	R	R	R	S	S	S	S	S	S	S	R	S	R	S	R	S
1614238	R	S	R	R	R	R	S	S	S	S	S	S	S	S	S	S	S	S	S
1614243	R	S	S	R	R	R	S	S	S	S	S	S	S	S	S	R	S	R	S
1614244	R	S	S	R	R	R	S	S	S	S	S	S	S	S	S	S	S	R	R
1614245	R	S	R	R	S	R	S	S	S	S	S	S	S	S	S	R	S	R	R
1614249	R	S	R	R	R	R	S	S	S	S	S	S	S	S	S	R	S	S	R
1614250	R	S	R	R	S	R	S	S	S	S	S	S	S	S	S	R	S	R	R
1614251	R	S	R	R	S	R	S	R	R	S	S	S	S	S	S	R	S	R	S
1614254	R	S	R	R	R	R	S	S	S	S	S	S	S	S	S	S	S	S	S
1614255	R	S	R	R	S	R	S	S	S	S	S	S	S	S	S	R	S	R	R
1614257	R	S	R	R	S	R	S	S	S	S	S	S	S	S	S	R	S	R	R
1614261	R	S	R	R	S	R	S	S	S	S	S	S	S	R	S	R	S	R	R
1614262	R	S	R	R	S	R	S	R	S	S	S	S	S	S	S	R	S	R	R
1614267	R	S	S	R	R	R	S	R	R	S	S	S	S	S	S	S	S	S	S
1614268	R	S	R	R	S	R	S	S	S	S	S	S	S	R	S	R	S	R	R
1614269	R	S	S	R	R	R	S	R	S	S	S	S	S	S	S	R	S	S	S
1614270	R	S	R	R	S	R	S	S	S	S	S	S	S	S	S	R	S	R	R
1614271	R	S	R	R	S	R	S	S	S	S	S	S	S	S	S	R	S	R	S
1614681	R	S	S	R	R	R	S	S	S	S	S	S	S	S	S	S	S	S	S
1614688	R	S	R	R	S	R	S	S	S	S	S	S	S	R	S	R	S	R	R
1614704	R	S	R	R	S	R	S	S	S	S	S	S	S	R	S	R	S	R	R
1614705	R	S	R	R	S	R	S	S	S	S	S	S	S	S	S	R	S	R	R
1614707	R	S	R	R	S	R	S	S	S	S	S	S	S	S	S	S	S	R	R

FINAL REPORT

1614708	R	S	S	R	R	R	S	S	S	S	S	S	S	S	S	S	S	S
1614709	R	S	S	R	R	R	S	R	R	S	S	S	S	S	S	S	S	S
1614710	R	S	R	R	S	R	S	S	S	S	S	S	S	S	R	S	R	S
1614712	R	S	R	R	S	R	S	R	R	S	S	S	S	S	R	S	R	R
1614713	R	S	S	R	R	R	S	S	S	S	S	S	S	S	S	S	S	S
1614714	R	S	R	R	S	R	S	R	R	S	S	S	S	S	R	S	R	R
1614716	R	S	S	R	R	R	S	R	R	S	S	S	S	S	S	S	R	R
1614718	R	S	R	R	S	R	S	S	S	S	S	S	S	S	R	S	R	S
1614719	R	S	R	R	S	R	S	S	S	S	S	S	S	S	R	S	R	S
1614723	R	S	R	R	S	R	S	S	S	S	S	S	S	S	R	S	R	S
1614735	R	S	R	R	S	R	S	S	S	S	S	S	S	S	R	S	R	R
1614738	R	S	S	R	R	R	S	S	S	S	S	S	S	S	S	S	S	S
1614739	R	S	R	R	S	R	S	S	S	S	S	S	S	S	R	S	R	S
1614745	R	S	S	R	R	R	S	S	S	S	S	S	S	S	S	S	S	S
1614749	R	S	R	R	S	R	S	S	S	S	S	S	S	S	R	S	R	R
1614753	R	S	R	R	S	R	S	S	S	S	S	S	S	S	R	S	R	S
1614756	R	S	R	R	S	R	S	S	S	S	S	S	S	S	S	S	R	R
1614760	R	S	R	R	S	R	S	R	R	S	S	S	S	S	R	S	R	S
1614762	R	S	R	R	S	R	S	S	S	S	S	S	S	S	R	S	R	S
1614763	R	S	R	R	S	R	S	S	S	S	S	S	S	S	R	S	R	S
1614764	R	S	R	S	S	R	S	R	R	S	S	S	S	S	R	S	R	S
1614765	R	S	R	R	S	R	S	S	S	S	S	S	S	S	R	S	R	R
1614766	R	S	R	R	S	R	S	R	R	S	S	S	S	S	R	S	R	S
1614904	R	S	R	R	S	R	S	S	S	S	S	S	S	S	R	S	R	R
1614908	R	S	R	R	S	R	S	S	S	S	S	S	S	S	R	S	R	R
1614911	R	S	R	R	S	R	S	S	S	S	S	S	R	S	R	S	R	R
1614913	R	S	R	R	S	R	S	S	S	S	S	S	S	S	R	S	R	R
1614914	R	S	R	R	S	R	S	S	S	S	S	S	S	S	R	S	R	S

FINAL REPORT

1614917	R	S	S	R	R	R	S	S	S	S	S	S	S	S	S	S	S	S	S
1614919	R	S	S	R	R	R	S	S	S	S	S	S	S	S	S	S	S	S	S
1614920	R	S	R	R	R	R	S	S	S	S	S	S	R	S	R	S	R	S	S
1614924	R	S	R	R	S	R	S	S	S	S	S	S	S	S	R	S	R	S	S
1614926	R	S	R	R	R	R	S	S	S	S	S	S	R	S	R	S	R	S	S
1614927	R	S	S	R	R	R	S	S	S	S	S	S	R	S	R	S	R	S	S

AMP – ampicillin (R > 8 mg/L); AZM – azithromycin (R > 16 mg/L); FEP – cefepime (R > 0.125 mg/L); CTX – cefotaxime (R > 0.25 mg/L); FOX – ceftaxime (R > 8); CAZ – ceftazidime (R > 8 mg/L); CHL – chloramphenicol (R > 16 mg/L); CIP – ciprofloxacin (R > 0.064 mg/L); NAL - nalidixic acid (R > 16 mg/L); CST – colistin (R > 2 mg/L); ETP – Ertapenem (R > 0.064 mg/L); IPM – Imipenem (R > 0.5 mg/L); MEM – Meropenem (R > 0.125 mg/L); GEN – gentamicin (R > 2 mg/L); TMC - temocillin (R > 32mg/L); TET – tetracycline (R > 8); TGC - tigecycline (R > 0.5); SUL – sulfamethoxazole (R > 64 mg/L); TMP - trimethoprim (R > 2 mg/L).

Interpretative criteria according to tables 1 and 4 in Commission Implementing Decision 2013/652/EU.

Table 7. Summary of resistance phenotypes for all isolates from MCA-CTX

Antibiotic	No. resistant ^a / No. tested	
	ESBL*	AmpC**
Ampicillin	93/93	48/48
Azithromycin	0/93	0/48
Cefepime	93/93	15/48
Cefotaxime	92/93	48/48
Cefoxitin	3/93*	48/48
Ceftazidime	93/93	48/48
Chloramphenicol	3/93	0/48
Ciprofloxacin	25/93	9/48
Colistin	0/93	0/48
Ertapenem	0/93	0/48
Gentamicin	10/93	13/48
Imipenem	0/93	0/48
Meropenem	0/93	0/48
Naladixic Acid	22/93	8/48
Sulfamethoxazole	91/93	19/48
Temocillin	0/93	0/48
Tetracycline	85/93	19/48
Tigecycline	0/93	0/48
Trimethoprim	47/93	7/48

Orange highlight denotes the four different cephalosporin antibiotics which were tested.

Grey highlight denotes the three carbapenem antibiotics ertapenem, imipenem and meropenem and colistin (all last resort antibiotics).

Green highlight denotes a lower proportion of ESBL versus AmpC or AmpC versus ESBL isolates resistant for stated antibiotic.

^a Microbiologically resistant using EUCAST ECOFFS.

* Includes the 3 isolates with an AmpC/ESBL phenotype which show resistance to cefoxitin

** Does not include the 3 isolates with an AmpC/ESBL phenotype

Table 8. Viable count of presumptive *E. coli* if above detection limit

Sample number	Supermarket code	Product text description	Dispatch date	Viable counts ^a (cfu/g) on agars	
				MCA-CTX	CA-ESBL
1364265	G	British Chicken Wings	10-Oct-2016	40	160
1364273	B	Whole Chicken	11-Oct-2016	0	120
1364303	B	Free Range corn-fed British chicken thighs	24-Aug-2016	0	40
1364325	K	Scottish Medium Whole Chicken	22-Aug-2016	0	120
1364332	A	Scottish Small Fresh Whole Chicken	23-Aug-2016	0	40
1612891	E	British Small Chicken	7-Dec-2016	0	280
1614244	F	British Chicken medium	19-Jan-2016	40	0
1614257	K	British Whole Chicken	18-Jan-2016	400	0
1614723	F	British Chicken 2 Breast Fillets skin-on	23-May-2016	120	160
1614739	K	British small whole chicken	11-Apr-2016	0	80
1614748	B	British Chicken	13-Apr-2016	0	40
1614765	K	British chicken thighs	22-Feb-2016	0	40

a – Limit of detection = 40 cfu/gram of meat

Table 9. PCR results (*bla*_{CTX}, *bla*_{OXA}, *bla*_{SHV} and *bla*_{TEM} genes) and CTX-M gene sequence for *E. coli* from CA-ESBL

Sample number	Supermarket code	Product text description	PCR results for <i>bla</i> _{CTX} , <i>bla</i> _{OXA} , <i>bla</i> _{SHV} and <i>bla</i> _{TEM} genes	CTX-M gene sequence
1364243	G	British chicken thighs	CTX,TEM	CTXM-15 / 15 WGS
1364250	B	British chicken medium	CTX	CTXM-1
1364251	G	British Chicken Medium	CTX	CTXM-1
1364252	I	British Whole Chicken	CTX	CTXM-1
1364254	A	100% British Small whole chicken	CTX,TEM	CTXM-1
1364255	D	Class A Fresh British Whole Medium Chicken	CTX	CTXM-1
1364258	K	British Chicken Thighs	CTX	CTXM-1
1364265	G	British Chicken Wings	CTX,TEM	CTXM-1
1364266	D	Class A fresh british whole small chicken	CTX	CTXM-1
1364273	B	Whole Chicken	CTX	CTXM-1
1364275	B	British Chicken Boneless Thigh Fillets	CTX	ND
1364277	G	British Chicken Thighs	CTX,TEM	CTXM-1
1364278	K	British Chicken Mini Fillets	CTX	CTXM-1
1364281	L	British Chicken Breast Fillet	CTX	CTXM-1
1364283	A	Chicken thigh fillets	CTX	CTXM-1
1364285	A	100% British Chicken Thigh Fillets	CTX	ND
1364290	K	Whole chicken	CTX	ND
1364293	I	British Corn Fed Whole Chicken	CTX,TEM	CTXM-1
1364303	B	Free Range Corn-fed British chicken thighs	CTX	CTXM-1
1364310	K	British Small Whole Chicken without giblets	CTX	CTXM-1
1364311	L	British Chicken without giblets	CTX	CTXM-1
1364314	K	British Chicken Mini Fillets	CTX	CTXM-1
1364323	B	British Chicken Breast Mini Filets	CTX	CTXM-1
1364325	K	Scottish Medium Whole Chicken	CTX	CTXM-1
1364328	K	Chicken Drumsticks	CTX	CTXM-1
1364332	A	Scottish Small Fresh Whole Chicken	CTX,TEM	CTXM-1
1364333	B	British Chicken Breast Fillets	CTX,TEM	CTXM-1
1364335	B	Scottish Chicken Medium	CTX	CTXM-1
1364342	I	Northern Irish Chicken Whole Breast Fillets	CTX	CTXM-1
1562692	K	British Chicken Fresh Class A	CTX	ND
1562695	K	Chicken Breast Mini-Fillets	CTX	CTXM-1
1562696	K	British Chicken Breast Mini-Fillets	CTX	CTXM-1
1562930	B	British chicken breast mini fillets	CTX	CTXM-1
1563611	L	British 2 Part Boned Breasts	CTX,TEM	CTXM-1
1563700	C	British Chicken Breast Fillets	CTX	ND
1563707	K	Chicken Breast Portions	CTX	CTXM-1
1563719	I	British chicken whole breast fillets	TEM	ND
1612878	K	British Small Whole Chicken	SHV	ND

Sample number	Supermarket code	Product text description	PCR results for <i>bla</i> _{CTX} , <i>bla</i> _{OXA} , <i>bla</i> _{SHV} and <i>bla</i> _{TEM} genes	CTX-M gene sequence
1612885	G	British Chicken	CTX	ND
1612887	K	British Chicken Thigh Fillets	CTX	ND
1612891	E	British Small Chicken	CTX	ND
1612903	C	British Chicken Breast Fillets	CTX	ND
1612904	C	British Whole Chicken	CTX	ND
1612913	C	British Chicken Thigh Fillets	CTX	ND
1614173	K	Free Range Whole Chicken	CTX,TEM	CTXM-1
1614175	B	British Chicken Breast Mini Fillets	TEM,SHV	ND
1614177	K	Chicken Breast Portions	CTX	CTXM-10
1614178	K	Whole Chicken	CTX	CTXM-1
1614180	I	British Chicken Thighs	CTX	CTXM-1
1614185	K	British Medium Whole Chicken	CTX	CTXM-1
1614188	A	Chicken Breast Fillets	CTX	CTXM-1
1614191	A	Small Whole Chicken.	CTX,TEM	CTXM-1
1614192	K	British Chicken Thighs	TEM,SHV	ND
1614193	K	British Medium Whole Chicken.	CTX	CTXM-1
1614194	G	British Chicken Breast Fillets	CTX	CTXM-1
1614198	B	Free Range Corn-fed British Whole Chicken	CTX	CTXM-1
1614201	E	British Chicken Free Range Breast Fillets	CTX	CTXM-1
1614208	G	British Chicken breast fillets	CTX	CTXM-1
1614210	F	Corn Fed Chicken Breast Fillets	CTX	CTXM-1
1614212	I	British Chicken Whole Breast Fillets	CTX,TEM	CTXM-1
1614219	G	British Chicken Breast Fillets	CTX	CTXM-1
1614229	K	British Whole Chicken	CTX	CTXM-1
1614233	B	British Chicken Fresh Class A	SHV,TEM	ND
1614243	G	British Diced Breast	Neg	ND
1614244	F	British Chicken medium	CTX,TEM	CTXM-15 / 55 WGS
1614245	K	British Chicken Breast Fillets skinless	CTX	CTXM-1
1614249	D	Fresh Whole Chicken without giblets	SHV	ND
1614250	A	Small Whole Chicken	CTX,TEM	CTXM-1
1614255	K	Chicken Breast Fillets skinless	CTX,TEM	CTXM-1
1614257	K	British Whole Chicken	CTX,TEM	CTXM-1
1614261	B	British Chicken Boneless Thigh Fillet	CTX	CTXM-1
1614262	A	Chicken Thighs	CTX	CTXM-1
1614268	K	Free Range Chicken Thigh Fillets	CTX	CTXM-28
1614270	A	Small Whole Chicken	CTX,TEM	CTXM-15 / 1 WGS
1614683	I	British Chicken whole breast fillets	CTX	CTXM-1
1614685	G	British chicken diced breast fillets	CTX	CTXM-1
1614688	B	British Chicken Wings	CTX	CTXM-1
1614718	K	British small whole chicken	CTX	CTXM-1

Sample number	Supermarket code	Product text description	PCR results for <i>bla</i> _{CTX} , <i>bla</i> _{OXA} , <i>bla</i> _{SHV} and <i>bla</i> _{TEM} genes	CTX-M gene sequence
1614719	B	British chicken	CTX	CTXM-1
1614723	F	British Chicken 2 Breast Fillets skin-on	CTX	CTXM-1
1614734	E	British Chicken Mini Fillets	CTX,SHV	CTXM-15 / 1 WGS
1614735	I	British Small whole chicken	CTX	CTXM-1
1614739	K	British small whole chicken	CTX	CTXM-32
1614741	G	Chicken Wings	CTX,TEM	CTXM-1
1614749	K	British Small Whole Chicken	CTX	CTXM-1
1614751	D	British whole small chicken	CTX	CTXM-1
1614753	K	Northern Irish medium whole chicken	CTX	CTXM-1
1614756	K	British whole chicken	CTX	CTXM-1
1614762	K	British 2 chicken breast fillets	CTX	CTXM-1
1614764	A	Chicken thigh fillets	CTX	CTXM-1
1614765	K	British chicken thighs	CTX	CTXM-1
1614766	G	British Chicken diced breast fillet	CTX	CTXM-1
1614911	I	British Chicken Mini Fillets	CTX	CTXM-1
1614914	L	British chicken breast fillets	CTX	CTXM-1
1614924	I	British small whole chicken	CTX	CTXM-1

NA – Not applicable; ND – Not determined; WGS – result by whole genome sequencing as part of previously discussed ResAlert.

Table 10. Results of whole genome sequencing using DTU (and APHA) pipelines for *E. coli* that were CTX-M 15 by sequencing of PCR amplicons

Sample Name	Species	MLST and O group	Plasmids	pMLSTs	Resistance Genes	APHA Resistance genes (differences DTU)*	Virulence Genes	Resistant to**
Bead LREC 3258 Meat sample 01364243 October	Escherichia coli	ST-38 O7:H18 (99.74%:96.65%)	Col(BS512) IncY	NA	tet(A) sul2 dfrA14 blaCTX-M-15 blaTEM-1B strA strB	+ qnrS1	eilA iss gad	
Bead LREC 2665 Meat sample 01614734 April	Escherichia coli	ST-10 O13:H48 (99.83%:100%)	IncX3 ColRNAI p0111 Col(MG828)	IncI1 [ST-3]	aadA1 sul2 QnrS1 dfrA1 tet(A) blaSHV-12 blaCTX-M-1	+ ant3-1a + sat2A	iss astA	
Bead LREC 2354 Meat sample 01614244 January	Escherichia coli	ST-3776 O166:H45 (99.53%:99.82%)	IncX1 ColRNAI	IncF [Unknown ST]	aac(3)-IId aadA17 sul3 QnrS1 dfrA14 tet(A) blaCTX-M-55 blaTEM-1B lnu(F)	- sul3	eilA iss	AMP, CTX, CAZ, SUL, TMP, FOX.
Bead LREC 2346 Meat sample 01614270 January	Escherichia coli	Unknown ST O?:H31 (ND:98.4%)	p0111 Col(MG828) ColRNAI	IncI1[ST-3] IncHI1 [Unknown ST] IncF [F18:A6*:B1]	aadA5 sul2 dfrA17 blaTEM-1B blaCTX-M-1 tet(A)		air lpfA iss eilA tsh iron	AMP, CTX, CAZ, SUL, TET, TMP, FEP.

* + and gene – gene detected by APHA but not by DTU pipeline;- and gene – gene detected by DTU but not APHA pipeline. Consensus otherwise. ** Resistant using EFSA cut-offs. Serotyping (% match to gene)

A Bacterial Analysis Platform: An Integrated System for Analysing Bacterial Whole Genome Sequencing Data for Clinical Diagnostics and Surveillance. Thomsen MCF, Ahrenfeldt J, Cisneros JLB, Jurtz V, Larsen MV, Hasman H, Aarestrup FM and Lund O. PLoS ONE, 2016, 11(6): e0157718. doi:10.1371/journal.pone.0157718

8. Discussion

Many different studies have shown that ESBL-producing *E. coli* can be detected on raw poultry meat in countries, such as the Netherlands, where one study showed that 94% of chicken meat samples were positive for ESBL-producing *E. coli*,⁵ in Germany in 2012, where 60% of 120 chicken meat samples purchased were positive for mainly CTX-M-1 ESBL-producing Enterobacteriaceae,⁶ in Portugal,⁷ and in the UK^{7,8}.

In the UK study carried out by Dhanji et al,⁷ found that 29.5% of 210 chicken meat samples imported in 2008 were positive for oxyimino-cephalosporin-resistant *E. coli*. Of the 141 isolates tested, 30% and 27% were positive for CTX-M groups 2 and 8 ESBL-producing genes respectively, whilst 42% were positive for AmpC CMY-type enzymes, and 1% produced a group 2 CTX-M along with a CMY enzyme.⁷ In a more recent study in which retail chicken meat samples were collected in 2013-2014 from 5 different regions in the UK, 65.4% of 159 samples were positive for mainly *bla*_{CTX-M-1} ESBL-producing *E. coli*, whilst *bla*_{CTX-M-15} ESBL-producing *E. coli* was not detected.

The 2014 EFSA summary report on antimicrobial resistance in zoonotic and indicator bacteria from humans, animals and food, did not report on any carbapenem resistant *E. coli* detected in chickens or turkeys in Europe.⁹ However, one study has shown that 65.09% and 11.32% of retail chicken in Egypt was positive for ESBL-producing or *bla*_{NDM} carbapenem resistant Enterobacteriaceae respectively.¹⁰

One of the problems of comparing results from different studies is that each study may use a slightly different enrichment technique and / or final isolation agar, and as such results are not truly comparable. For current and on-going EU studies however, all participants are using identical methodologies and sample sizes, so results will be comparable across member states.

For the UK study conducted in 2013-2014, enrichment of meat samples in BPW, followed by plating to CHROMagar ESBL and CHROMagar CTX was employed.³ For the EU survey reported here, samples were also enriched in BPW, and then plated to MCA-CTX and CA-ESBL.³ As such the isolation methods between the two surveys was similar. The sample collection for the 2013-2014 survey, although not identical to that performed in the current study, did involve purchase of meat samples from local retailers in each of five UK regions (London, East Anglia, the North West, Scotland and Wales) in numbers that were representative of UK market share, and samples were purchased on five different occasions over a ~ 7 month period.³ Comparing the findings of the 2013-2014 study³ and this study, it

was encouraging that a drop from 65.4% to 29.7% of retail chicken samples being positive for ESBL-producing *E. coli* in the UK was observed. This difference was statistically significant using a chi-squared test (odds ratio 0.45 p-value<0.001), however, it should be noted that the slightly different sampling criteria and sample processing methods used in the current study could have influenced results.

In Denmark, cephalosporin antibiotics have not been used in poultry for more than 10 years, and it has been considered that the high prevalence of AmpC/ESBL-producing bacterial detected in Danish broiler meat might be caused by practices upstream in the production pyramid, since the breeding company supplying birds until recently used cephalosporin antibiotics as a prophylactic measure.¹¹ In 2012, the use of third generation cephalosporins in chicks destined for broiler parent flocks in UK was stopped voluntarily, as was any occasional use for commercial generations of laying hens and broilers.¹² It is likely that this would take a while to have an effect on cephalosporins resistance in *E. coli* from chicken meat, for example until the progeny of these parents were placed. Some persistent resistance on farm should also have reduced further over time.

In Quebec Canada, higher rates of ceftiofur resistance in *Salmonella* Heidelberg isolates from chicken meat than from humans, prompted broiler chicken hatcheries to voluntarily interrupt the extra-label in-ovo use of ceftiofur during 2005-2006.¹³ This ban was associated with a decrease in the prevalence of ceftiofur resistance from 2004 to 2006 among retail chicken (62% to 7%; p<0.001) and human (36% to 8%; p<0.0001) *Salmonella* Heidelberg isolates and retail chicken *E. coli* isolates (34% to 6%; p<0.0001), which was reversed when ceftiofur use was reintroduced.¹³ The study concluded that changes in ceftiofur resistance *E. coli* and *Salmonella* Heidelberg in retail chicken meat appeared to be related to changing levels of ceftiofur use in hatcheries.¹³ Whilst it is not possible to categorically state that the drop from 65.4% to ~ 30% of retail chicken samples being positive for ESBL-producing *E. coli* in the UK between the years 2013-2014 and 2016 is directly related to the voluntary cessation of third generation cephalosporins in 2012 in chicks destined for broiler parent flocks in UK, it would seem probable, based on similar findings seen in the Canadian study.¹³

In this study and the UK study of 2013-2014, the predominant CTX-M sequence type was CTX-M1.³ This therefore differs from the CTX-M group 2 and 8 *E. coli* isolates found on imported chicken in an earlier study.⁷

The predominant *E. coli* strain associated with human infections is the pandemic O25-ST131 CTX-M-15-producing clone.^{14, 15} Whilst four isolates of *E. coli* that were *bla*_{CTX-M15} were

detected by PCR, whole genome sequencing of these isolates showed that none were the pandemic O25-ST131 CTX-M-15-producing clone and only one of the four isolates was confirmed as CTX-M-15 by WGS. As such, the evidence would suggest that at present in the UK, ESBL-producing *E. coli* from retail chicken differs from the predominant strain in humans and retail chicken is not a source of the human pandemic O25-ST131 CTX-M-15-producing clone. This was also the overarching finding of recent work performed by PHE,¹⁶ in that ESBL-producing *E. coli* from humans (blood, faeces, and including sewage) were largely distinct from those present in raw meat, live animals and farm slurry, with ST131 hugely dominant as a cause of human disease. Even after excluding ST131, the next *E. coli* type in rank, overall and in each of the human sources, was ST38 (9.4% in sewage isolates, 8.0% in human faeces and 5.8% in bacteraemia isolates, ~ 40% of all ST38 isolates were CTX-M 15), and no ST38 isolates were found in the meat, slurry or scanning animal surveillance isolates, again suggesting that it is a ‘human-adapted’ strain.¹⁶ Although one isolate in this study was CTX-M 15 ST38, WGS results showed that the isolate was different from human ST38 isolates recovered as part of the recent PHE project.¹⁶

With respect to the degree of contamination of chicken samples with presumptive AmpC/ESBL *E. coli*, whilst overall 45.1% of samples were positive on MCA-CTX agar for AmpC/ESBL-producing *E. coli*, only 3.8% of samples had counts above the detection limit on CA-ESBL or MCA-CTX, suggesting that for most positive samples, the levels of AmpC or ESBL producing *E. coli* on the samples was very low.

None of the 141 isolates from MCA-CTX were microbiologically resistant to the last resort carbapenem antibiotics ertapenem, imipenem and meropenem or to colistin. This correlates with the findings of the 2014 EFSA report for *E. coli* from chickens and turkeys, in that none of the isolates were resistant to carbapenem antibiotics, and only low numbers of isolates were resistant to colistin.⁹ Whilst nine of the samples gave rise to lactose fermenting colonies on MCA-COL, these were negative for plasmid mediated colistin resistance genes *mcr-1* and *mcr-2*. Additionally, none of the isolates were resistant to the antibiotics azithromycin, temocillin and tigecycline. Most or several of the isolates were resistant to the antibiotics sulfamethoxazole (78.0%), tetracycline (74.5%) and trimethoprim (38.3%), and about 25% of the isolates were resistant to the quinolone antibiotics nalidixic acid and ciprofloxacin.

9. Conclusions

- Of the 313 UK retail chicken samples tested, 93 (29.7%) and 51 (16.3%) (including AmpC/ESBL phenotype isolates) were positive for ESBL or AmpC phenotype *E. coli* respectively, based on results from MCA-CTX agar and MICs to determine AmpC or ESBL phenotype.
- Using CA-ESBL, 95 (30.4%) of samples were positive for presumptive ESBL phenotype *E. coli*, of which 93 (29.7%) were confirmed by PCR to be *bla*_{CTX-M} (mainly CTX-M 1) or *bla*_{SHV} positive. This therefore shows a good correlation of results between MCA-CTX coupled with phenotypic testing for ESBLs, and use of an ESBL selective agar (CA-ESBL), coupled with PCR.
- The predominant CTX M types recovered from retail chicken (mainly CTX-M-1) differ to those causing human disease.
- None of the samples were positive for carbapenem resistant *E. coli*.
- None of the samples were positive for *E. coli* with plasmid mediated colistin resistance genes *mcr-1* and *mcr-2*.
- Only 12 meat samples (3.8%) had viable counts (without enrichment) of presumptive AmpC or ESBL-producing *E. coli* above the detection limit (40 cfu/gram), and these counts were all less than or equal to 400 cfu/gram.
- Results showed a decrease in the proportion of samples positive for ESBL-producing *E. coli* compared to a previous (2013-2014) UK study that reported that 65.4% of 159 retail chicken samples were positive for ESBL-producing *E. coli*. This difference was statistically significant using a chi-squared test (odds ratio 0.45 p-value<0.001), however, it should be noted that the slightly different sampling criteria and sample processing methods used in the current study could have influenced results.

10. References

1. Fang H, Ataker F, Hedin G et al. Molecular epidemiology of extended-spectrum beta-lactamases among *Escherichia coli* isolates collected in a Swedish hospital and its associated health care facilities from 2001 to 2006. *J Clin Microbiol* 2008; **46**: 707-12.
2. Anonymous. Final Report for FS102109 EU Harmonised Survey of Antimicrobial Resistance (AMR) on Retail Meats. *Report of Hallmark Veterinary compliance services* 2017.
3. Randall LP, Lodge MP, Elviss NC et al. Evaluation of meat, fruit and vegetables from retail stores in five United Kingdom regions as sources of extended-spectrum beta-lactamase (ESBL)-producing and carbapenem-resistant *Escherichia coli*. *International Journal of Food Microbiology* 2017; **241**: 283-90.
4. Randall LP, Lemma F, Koylass M et al. Evaluation of MALDI-ToF as a method for the identification of bacteria in the veterinary diagnostic laboratory. *Res Vet Sci* 2015; **101**: 42-9.
5. Leverstein-van Hall MA, Dierikx CM, Cohen Stuart J et al. Dutch patients, retail chicken meat and poultry share the same ESBL genes, plasmids and strains. *Clin Microbiol Infect* 2011; **17**: 873-80.
6. Campos BC, Fenner I, Wiese N et al. Prevalence and genotypes of extended spectrum beta-lactamases in Enterobacteriaceae isolated from human stool and chicken meat in Hamburg, Germany. *Int J Med Microbiol* 2014; **304**: 678-84.
7. Dhanji H, Murphy NM, Doumith M et al. Cephalosporin resistance mechanisms in *Escherichia coli* isolated from raw chicken imported into the UK. *J Antimicrob Chemother* 2010; **65**: 2534-7.
8. Warren RE, Ensor VM, O'Neill P et al. Imported chicken meat as a potential source of quinolone-resistant *Escherichia coli* producing extended-spectrum beta-lactamases in the UK. *J Antimicrob Chemother* 2008; **61**: 504-8.
9. EFSA. The European Union summary report on antimicrobial resistance in zoonotic and indicator bacteria from humans, animals and food in 2014. *EFSA Journal* 2016; **14**: 1-207.
10. Abdallah HM, Reuland EA, Wintermans BB et al. Extended-Spectrum β -Lactamases and/or Carbapenemases-Producing Enterobacteriaceae Isolated from Retail Chicken Meat in Zagazig, Egypt. *PLOSone* 2015; **10**: 1-8.
11. Carmo LP, Nielsen LR, da Costa PM et al. Exposure assessment of extended-spectrum beta-lactamases/AmpC beta-lactamases-producing *Escherichia coli* in meat in Denmark. *Infection ecology & epidemiology* 2014; **4**.
12. British-poultry-council. Leading the way in the responsible use of antibiotics. <https://www.nfuonline.com/assets/61352>.

13. Dutil L, Irwin R, Finley R et al. Ceftiofur resistance in *Salmonella enterica* serovar Heidelberg from chicken meat and humans, Canada. *Emerg Infect Dis* 2010; **16**: 48-54.
14. Pomba C, da Fonseca JD, Baptista BC et al. Detection of the pandemic O25-ST131 human virulent *Escherichia coli* CTX-M-15-producing clone harboring the qnrB2 and aac(6)-Ib-cr genes in a dog. *Antimicrob Agents Chemother* 2009; **53**: 327-8.
15. Nicolas-Chanoine MH, Bertrand X, Madec JY. *Escherichia coli* ST131, an intriguing clonal group. *Clin Microbiol Rev* 2014; **27**: 543-74.
16. PHE. Defining reservoirs of ESBL-producing *E. coli* and the threat posed to personal, animal and public health in the UK. *In-press* 2017.